GERON CORP Investing Cash Flow
GERON CORP (GERN) reported Investing Cash Flow of $60.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- GERON CORP net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $8.29M, a 59.17% decline year-over-year.
- GERON CORP net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $51.86M, a 1.11% decline year-over-year.
- GERON CORP net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $21.14M.
- GERON CORP net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $13.35M.
- GERON CORP net cash provided by (used in) investing activities for fiscal 2025 was $107.25M.
- GERON CORP net cash provided by (used in) investing activities for fiscal 2024 was -$106.00M.
- GERON CORP net cash provided by (used in) investing activities for fiscal 2023 was -$180.32M, a 390.53% decline from fiscal 2022.
- GERON CORP net cash provided by (used in) investing activities for fiscal 2022 was $62.07M, a 13.73% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $60.15M 10-Q · filed 2026-08-05 | $81.30M derived: sum of 3 quarters · filed 2026-08-05 | $94.64M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $51.86M 10-Q · filed 2026-05-06 | $73.00M derived: sum of 2 quarters · filed 2026-05-06 | $86.35M derived: sum of 3 quarters · filed 2026-05-06 | $106.66M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $21.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $34.49M derived: sum of 2 quarters · filed 2026-03-02 | $54.81M derived: sum of 3 quarters · filed 2026-08-05 | $107.25M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $13.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $33.66M derived: sum of 2 quarters · filed 2026-08-05 | $86.10M 10-Q · filed 2025-11-07 | -$17.41M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $20.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $72.75M 10-Q · filed 2026-08-05 | -$30.76M derived: sum of 3 quarters · filed 2026-08-05 | -$31.31M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $52.44M 10-Q · filed 2026-05-06 | -$51.07M derived: sum of 2 quarters · filed 2026-05-06 | -$51.63M derived: sum of 3 quarters · filed 2026-05-06 | -$87.77M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$103.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$104.06M derived: sum of 2 quarters · filed 2026-03-02 | -$140.21M derived: sum of 3 quarters · filed 2026-03-02 | -$106.00M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$36.70M derived: sum of 2 quarters · filed 2025-11-07 | -$2.49M 10-Q · filed 2025-11-07 | $45.08M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | -$36.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.94M 10-Q · filed 2025-08-06 | $45.63M derived: sum of 3 quarters · filed 2026-03-02 | $40.92M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $34.21M 10-Q · filed 2025-05-07 | $81.78M derived: sum of 2 quarters · filed 2026-03-02 | $77.06M derived: sum of 3 quarters · filed 2026-03-02 | $32.62M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | $47.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $42.85M derived: sum of 2 quarters · filed 2026-03-02 | -$1.59M derived: sum of 3 quarters · filed 2026-03-02 | -$180.32M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$49.16M derived: sum of 2 quarters · filed 2024-11-07 | -$227.89M 10-Q · filed 2024-11-07 | -$208.90M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$44.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$223.18M 10-Q · filed 2024-08-08 | -$204.19M derived: sum of 3 quarters · filed 2025-02-27 | -$194.35M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$178.73M 10-Q · filed 2024-05-02 | -$159.75M derived: sum of 2 quarters · filed 2025-02-27 | -$149.90M derived: sum of 3 quarters · filed 2025-02-27 | -$147.09M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $18.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $28.83M derived: sum of 2 quarters · filed 2025-02-27 | $31.64M derived: sum of 3 quarters · filed 2025-02-27 | $62.07M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $9.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $12.65M derived: sum of 2 quarters · filed 2023-11-02 | $43.08M 10-Q · filed 2023-11-02 | $51.44M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $33.24M 10-Q · filed 2023-08-03 | $41.60M derived: sum of 3 quarters · filed 2024-02-28 | $36.20M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $30.43M 10-Q · filed 2023-05-11 | $38.79M derived: sum of 2 quarters · filed 2024-02-28 | $33.39M derived: sum of 3 quarters · filed 2024-02-28 | $64.29M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $8.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.96M derived: sum of 2 quarters · filed 2024-02-28 | $33.86M derived: sum of 3 quarters · filed 2024-02-28 | $71.95M 10-K · filed 2024-02-28 | |
| 2021-09-30 | -$5.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $25.50M derived: sum of 2 quarters · filed 2022-11-07 | $63.58M 10-Q · filed 2022-11-07 | $41.75M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-06-30 | $30.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $68.99M 10-Q · filed 2022-08-11 | $47.15M derived: sum of 3 quarters · filed 2023-03-16 | $60.72M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-03-31 | $38.08M 10-Q · filed 2022-05-09 | $16.25M derived: sum of 2 quarters · filed 2023-03-16 | $29.81M derived: sum of 3 quarters · filed 2023-03-16 | -$99.39M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2020-12-31 | -$21.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$8.27M derived: sum of 2 quarters · filed 2023-03-16 | -$137.48M derived: sum of 3 quarters · filed 2023-03-16 | -$105.32M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $13.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$115.64M derived: sum of 2 quarters · filed 2021-11-09 | -$83.48M 10-Q · filed 2021-11-09 | -$90.50M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$129.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$97.05M 10-Q · filed 2021-08-16 | -$104.06M derived: sum of 3 quarters · filed 2022-03-10 | -$98.02M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $32.16M 10-Q · filed 2021-05-10 | $25.14M derived: sum of 2 quarters · filed 2022-03-10 | $31.18M derived: sum of 3 quarters · filed 2022-03-10 | $50.59M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | -$7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$976.00K derived: sum of 2 quarters · filed 2022-03-10 | $18.44M derived: sum of 3 quarters · filed 2022-03-10 | $27.40M 10-K · filed 2022-03-10 | |
| 2019-09-30 | $6.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $25.45M derived: sum of 2 quarters · filed 2020-11-05 | $34.41M 10-Q · filed 2020-11-05 | $35.26M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-06-30 | $19.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $28.38M 10-Q · filed 2020-08-06 | $29.22M derived: sum of 3 quarters · filed 2021-03-11 | $19.88M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-03-31 | $8.96M 10-Q · filed 2020-05-28 | $9.81M derived: sum of 2 quarters · filed 2021-03-11 | $463.00K derived: sum of 3 quarters · filed 2021-03-11 | -$66.15M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2018-12-31 | $848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$8.50M derived: sum of 2 quarters · filed 2021-03-11 | -$75.11M derived: sum of 3 quarters · filed 2021-03-11 | -$77.72M 10-K · filed 2021-03-11 | |
| 2018-09-30 | -$9.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$75.96M derived: sum of 2 quarters · filed 2019-11-06 | -$78.57M 10-Q · filed 2019-11-06 | -$68.82M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-06-30 | -$66.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$69.22M 10-Q · filed 2019-08-01 | -$59.47M derived: sum of 3 quarters · filed 2020-03-12 | -$51.75M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-03-31 | -$2.61M 10-Q · filed 2019-05-02 | $7.14M derived: sum of 2 quarters · filed 2020-03-12 | $14.86M derived: sum of 3 quarters · filed 2020-03-12 | $11.00M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2017-12-31 | $9.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $17.47M derived: sum of 2 quarters · filed 2020-03-12 | $13.61M derived: sum of 3 quarters · filed 2020-03-12 | $22.97M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $7.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $3.87M derived: sum of 2 quarters · filed 2018-11-01 | $13.23M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | -$3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $5.50M 10-Q · filed 2018-07-31 | |||
| 2017-03-31 | $9.36M 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $8.76M 10-K · filed 2019-03-07 | $8.76M 10-K · filed 2018-03-16 | |||
| 2016-06-30 | -$2.90M 10-Q · filed 2017-08-09 | ||||
| 2015-12-31 | $73.00K 10-K · filed 2018-03-16 | ||||
| 2012-06-30 | $8.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $28.29M 10-Q · filed 2012-08-03 | $35.97M derived: sum of 3 quarters · filed 2012-08-03 | $47.91M derived: sum of 4 quarters · filed 2012-08-03 | |
| 2012-03-31 | $19.51M 10-Q · filed 2012-05-07 | $27.20M derived: sum of 2 quarters · filed 2012-05-07 | $39.14M derived: sum of 3 quarters · filed 2012-05-07 | $49.65M derived: sum of 4 quarters · filed 2012-08-03 | |
| 2011-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | $19.63M derived: sum of 2 quarters · filed 2012-03-07 | $30.14M derived: sum of 3 quarters · filed 2012-08-03 | $32.14M 10-K · filed 2012-03-07 | |
| 2011-09-30 | $11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $22.45M derived: sum of 2 quarters · filed 2012-08-03 | $24.45M 10-Q · filed 2011-11-03 | -$41.80M derived: sum of 4 quarters · filed 2012-08-03 | |
| 2011-06-30 | $10.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $12.51M 10-Q · filed 2012-08-03 | -$53.74M derived: sum of 3 quarters · filed 2012-08-03 | -$47.64M derived: sum of 4 quarters · filed 2012-08-03 | |
| 2011-03-31 | $2.00M 10-Q · filed 2012-05-07 | -$64.25M derived: sum of 2 quarters · filed 2012-05-07 | -$58.14M derived: sum of 3 quarters · filed 2012-05-07 | ||
| 2010-12-31 | -$66.25M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | -$60.15M derived: sum of 2 quarters · filed 2012-03-07 | -$48.45M 10-K · filed 2012-03-07 | ||
| 2010-09-30 | $6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $17.80M 10-Q · filed 2011-11-03 | |||
| 2010-06-30 | $11.70M 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | -$83.00M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |